Moisturizer Regulatory Labelling: EU, FDA & NMPA Cosmetic Label Requirements

Overview #

Regulatory labelling is not a box-ticking exercise. For moisturizers and creams, it is the single most common reason we see finished products held at customs, rejected by retailers, or pulled from shelves — and in almost every case, the brand owner didn’t know there was a problem until it was too late. The EU, FDA, and NMPA each operate under fundamentally different frameworks, and what passes in one market can trigger a compliance failure in another. We’ve onboarded enough international brand partners to know that the labelling conversation needs to happen before formulation is locked, not after.

How the Three Regulatory Frameworks Actually Differ #

Most brand owners come to us thinking label compliance is just translation. It isn’t.

Under EU Cosmetics Regulation 1223/2009, every cosmetic product placed on the EU market requires a Responsible Person (RP) established within the EU or EEA. The RP’s name and address must appear on the label — not just in the Product Information File. This catches a lot of brands off guard, especially post-Brexit, where a UK address no longer qualifies. Ingredient listing follows INCI nomenclature in descending order of concentration, with ingredients below 1% listed in any order after those above 1%. Fragrance allergens above 0.001% in leave-on products (10 ppm) must be individually declared — and that threshold is tightening. The SCCS Scientific Opinion on fragrance allergens has been pushing toward expanded declaration lists, and we now advise all EU-bound moisturizer briefs to assume the stricter forthcoming thresholds from day one.

The FDA operates under a completely different philosophy. In the US, moisturizers are regulated as cosmetics under the Federal Food, Drug, and Cosmetic Act, and the FDA Cosmetics Guidelines do not require pre-market approval. But the labelling rules are strict in their own way: the principal display panel must carry the product identity and net quantity of contents, and the information panel must list ingredients under “Ingredients:” using INCI names in descending order. Where brands trip up is the drug-cosmetic boundary. The moment a moisturizer claim crosses into therapeutic territory — “reduces wrinkles caused by UV damage,” for instance — the FDA may classify it as an OTC drug, triggering an entirely different compliance pathway. We push back on claim language constantly.

NMPA is the most documentation-intensive of the three. Under China’s NMPA Cosmetic Regulation, ordinary cosmetics (普通化妆品) require filing (备案) rather than registration, but the label must match the filed formula exactly — ingredient names, order, and concentration ranges. Chinese INCI equivalents (化妆品原料) must be used, and the label must include the filing number once approved. One thing that surprises brands: China requires the full ingredient list to appear on the outer packaging AND the immediate container if space permits. We’ve had projects where the primary packaging was too small to carry the full list, and we had to redesign the container before filing could proceed.

Where Most Brands Get the Claims Wrong #

This is usually where projects go sideways.

Efficacy claims on moisturizer labels are not just a marketing decision — they are a regulatory classification trigger. In the EU, a claim like “repairs the skin barrier” sits in cosmetic territory. “Treats atopic dermatitis” does not. The line sounds obvious, but in practice, brand copywriters push it constantly, and we’ve had to reject final label copy at the print-ready stage because a claim would have reclassified the product.

The EU’s Common Criteria for Cosmetic Claims — Regulation 655/2013 — sets six criteria that all cosmetic claims must meet: legal compliance, truthfulness, evidential support, honesty, fairness, and informed decision-making. “Evidential support” is the one that matters most for moisturizers. If you claim “clinically proven hydration,” you need substantiation data. We help brand partners design consumer perception studies and instrumental measurement protocols specifically to support these claims — more on that below.

In China, the NMPA maintains a prohibited and restricted claims list that is updated periodically. Claims implying medical function (医疗功效) are prohibited outright. More practically, superlative claims — “best,” “most effective,” “number one” — are restricted and require substantiation or are banned entirely. We’ve seen filing rejections purely on claim language, which delays market entry by 3–6 months.

Honestly, most brands underestimate how much the claims conversation affects formulation decisions. If a brand wants to claim “48-hour hydration,” we need to design the formula and run the corneometry study before the label is printed. The claim and the formula have to be developed together.

Instrumental Measurement and Consumer Study Design for Label Substantiation #

This is where the article angle gets practical. If you’re going to put a hydration or barrier claim on a moisturizer label, you need data behind it — and the study design determines whether that data is defensible.

For moisturizer efficacy, the two most common instrumental methods are corneometry (measuring skin capacitance as a proxy for stratum corneum hydration) and TEWL (transepidermal water loss, measured by Tewameter or similar closed-chamber devices). Corneometry gives you a hydration score; TEWL gives you barrier function data. A well-designed study uses both. We typically run a 12-week study with measurements at baseline, week 4, week 8, and week 12, with a 2-week washout period at the end to assess residual effect.

One clinical reference we use internally: a double-blind, randomized, vehicle-controlled study (n=42, 12 weeks) evaluating a ceramide-niacinamide moisturizer showed a 34% increase in corneometer scores from baseline at week 12, and a 28% reduction in TEWL versus vehicle control. That’s the kind of data that supports a “strengthens the skin barrier” claim in the EU. What it doesn’t tell you — and what we’ve learned from running our own stability and efficacy batches — is that the corneometer response is highly sensitive to ambient humidity during measurement. If your CRO doesn’t control for room humidity at 40–50% RH during testing, the data variance can swallow your effect size.

Consumer perception panels are a different instrument entirely. For a 12-week moisturizer study, we recommend a minimum panel size of 30 subjects for a single-arm open-label study, or 40 per arm for a split-face or parallel-group design. Questionnaires should be validated — we use adapted versions of the DLQI (Dermatology Life Quality Index) for sensitive skin claims, and custom 10-point Likert scales for sensory attributes like “skin feels softer,” “absorbs quickly,” and “non-greasy finish.” The consumer perception data supports the label claim; the instrumental data substantiates it scientifically.

Before/after photography protocol is often an afterthought. It shouldn’t be. Standardized photography requires fixed lighting (we use a cross-polarized setup at 45° incident angle), fixed camera distance, fixed subject positioning, and ideally the same photographer throughout the study. We’ve seen brand partners submit photography from a CRO where the lighting changed between week 0 and week 12 — the images were unusable for marketing. That’s a waste of 12 weeks and a significant budget.

For our moisturizer and cream development process, the study design is built into the project timeline from brief intake. We don’t treat efficacy substantiation as an add-on.

Designing a 12-Week Moisturizer Efficacy Study #

Here’s how we structure it when a brand partner needs label-ready data.

Weeks 1–2: Baseline and washout. Subjects stop using any active moisturizer for 14 days before baseline measurements. This is non-negotiable — residual product effects contaminate baseline corneometry readings. We’ve seen baseline TEWL values that were clearly suppressed because subjects hadn’t completed washout properly, and the study had to be restarted.

Week 0: Baseline measurements. Corneometry, TEWL, and photography under standardized conditions. Consumer questionnaire administered. Subjects randomized if parallel-group design.

Weeks 1–12: Treatment phase. Twice-daily application, morning and evening, to designated test sites (typically volar forearm for instrumental, full face for consumer perception). Compliance is tracked via diary — we require ≥80% compliance for a subject’s data to be included in the per-protocol analysis.

Measurement timepoints: Week 4, Week 8, Week 12. Instrumental measurements always taken 12–16 hours after last product application to avoid acute occlusion effects. Photography at week 0 and week 12 only — mid-study photography adds cost without adding claim value.

Week 14: Washout follow-up (optional but recommended for “long-lasting” claims). If you want to claim residual benefit after stopping use, you need this data point. Most brands skip it. We recommend it.

The full study costs vary significantly depending on CRO location and panel size, but for a 40-subject parallel-group design with full instrumental panel, budget 8–14 weeks of CRO time and plan for a 6-month total timeline from brief to final report. That timeline needs to be factored into your launch schedule — which is why we raise it at the first brief meeting, not at the packaging approval stage.

For brands developing barrier-repair or sensitive skin moisturizers, the study design overlaps significantly with our barrier repair and sensitive skin formulation approach, and we often co-design the efficacy protocol alongside the formula development.

A Scale-Up Note Nobody Talks About #

Lab-scale stability and a clean efficacy study don’t guarantee production-scale performance. We had one ceramide moisturizer project — passed all 12-week stability at 500g lab scale, clean corneometry data from the pilot study — where the production batch at 200kg showed phase separation at week 6 of accelerated stability testing. The root cause was shear rate differential during emulsification at scale. The ceramide lamellar structure that formed beautifully in the lab mixer didn’t replicate under the high-shear homogenizer at production speed.

We caught it before the brand launched. But it added 10 weeks to the timeline and required a full reformulation of the emulsifier system. The efficacy study had to be repeated on the reformulated batch. That’s not a hypothetical — it happened, and it’s why we now require a 20kg pilot batch stability check before any efficacy study is commissioned on a new moisturizer formula.

It’s not a perfect solution. But it’s better than repeating a 12-week study.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack?

That’s the first question we ask when a moisturizer brief comes in. Because “moisturizer” covers everything from a 5% glycerin lotion for the mass market to a 3% ceramide + 5% niacinamide barrier cream targeting EU dermatology retail — and the label requirements, claim substantiation pathway, and study design are completely different for each.

If you’re targeting the EU, we need to know your Responsible Person before we finalize the label template. If you don’t have one, we can refer you to RP service providers we’ve worked with, but that relationship needs to be established before CPNP notification. For FDA-market products, the claims review happens at brief stage — we flag anything that risks OTC drug classification immediately. For NMPA filing, we build the ingredient list in Chinese INCI format from day one, because retrofitting it after formulation lock creates errors.

On study design: if you want a hydration claim, plan for a minimum 4-week corneometry study with n=30. If you want a barrier claim, add TEWL measurement and extend to 8–12 weeks. If you want before/after photography for marketing use, budget for a standardized photography protocol from week 0. Tell us the claim first. We’ll design the formula and the study to support it.

MOQ and packaging also affect labelling. Airless pump packaging — which we often recommend for preservative-sensitive formulas — adds approximately $0.50–$0.90 per unit at MOQ 3,000 units. That cost needs to be in the business model before the label is designed around it.

Frequently Asked Questions #

Q: We want to say “clinically proven 48-hour hydration” on the label — what do we actually need to back that up?

You need a corneometry study with a measurement at 48 hours post-application, showing statistically significant improvement versus baseline or vehicle control. Minimum n=20 for a single-arm study, though n=30 gives you more defensible statistics. The claim also needs to be reviewed against EU Regulation 655/2013 criteria if you’re selling in Europe — “clinically proven” is a strong qualifier and the substantiation file needs to match it exactly.

Q: Does our moisturizer need NMPA filing if we’re only selling through cross-border e-commerce into China?

Cross-border e-commerce (跨境电商) into China operates under a different pathway than general trade, and ordinary cosmetics sold via CBEC platforms currently require filing (备案) under the NMPA framework. The rules have been tightening since 2021 — as of our last project review, filing is required for most categories including moisturizers. Check the current NMPA guidance directly, because this is still evolving.

Q: Can we list our fragrance as just “Parfum” on the EU label, or do we need to break it out?

“Parfum” covers the fragrance blend, but any individual fragrance allergen present above 10 ppm in a leave-on product must be declared separately by INCI name. The current EU list covers 26 allergens, and the SCCS has recommended expanding this list significantly. We now formulate EU-bound moisturizers with fragrance allergen screening as a standard step — it’s faster to catch it at formulation than at label review.

Q: We’re a US brand launching in the EU. Do we need a separate EU label, or can we use one label for both markets?

You need separate labels, or at minimum a label that satisfies both sets of requirements simultaneously — which is harder than it sounds. The EU requires the Responsible Person’s EU address on the label; the FDA requires net quantity in US customary units (oz/fl oz) as well as metric. The claim language also needs to be reviewed for both markets independently. In practice, most of our dual-market clients run two label versions.

Q: How long does NMPA filing take for a new moisturizer, and does it affect our launch timeline?

For ordinary cosmetics (普通化妆品) filing via the online system, the technical review timeline is typically 15–30 working days once the dossier is accepted, but dossier preparation — including formula documentation, safety assessment, and label review — adds 4–8 weeks on our end. Total timeline from brief to filing acceptance: plan for 3–4 months minimum. We’ve seen it done faster, but not reliably. Build it into your launch schedule from day one.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.